Related Experiment Video
Updated: Feb 22, 2026
14:57
Yeast As a Chassis for Developing Functional Assays to Study Human P53
Published on: August 4, 2019
10.1K
Multifunctional p62 Effects Underlie Diverse Metabolic Diseases
1Department of Endocrinology, Translational Research Key Laboratory for Diabetes, Xinqiao Hospital, Third Military Medical University, Chongqing 400037, China; These authors contributed equally to this work.
Trends in Endocrinology and Metabolism: TEM
|October 3, 2017
Summary
The protein p62 regulates key cellular processes and is increasingly recognized for its role in metabolic diseases like obesity and T2DM. Further research into p62
Area of Science:
- Molecular Biology
- Cell Biology
- Metabolic Disease Research
Background:
- p62 protein is a known regulator in cancer and neurodegenerative diseases.
- Emerging evidence highlights p62's pivotal role in metabolic diseases including obesity, T2DM, NAFLD, metabolic bone disease, gout, and thyroid disease.
Purpose of the Study:
- To review the emerging role of p62 in metabolic diseases.
- To explore p62's functional domains, animal model phenotypes, clinical alterations, and effects on metabolic signaling pathways.
- To identify research gaps concerning p62 in the gastrointestinal environment and immune system.
Main Methods:
- Literature review focusing on p62's involvement in metabolic disorders.
- Analysis of functional domains and genetic modifications related to p62.
- Examination of clinical data and downstream signaling pathways affected by p62.
Main Results:
- p62 is implicated as a key regulator across a spectrum of metabolic diseases.
- Functional domains, genetic alterations, and signaling pathways provide insights into p62's mechanisms.
- Elevated p62 expression may offer protection against metabolic disorders.
Conclusions:
- p62 is a significant factor in the pathogenesis and potential treatment of metabolic diseases.
- Further investigation is needed to fully elucidate p62's functions in the gut and immune system.
- Targeting p62 may represent a therapeutic strategy for metabolic disorders.
Related Concept Videos
02:23Abnormal Proliferation
5.3K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.3K
01:19Interactions Between Signaling Pathways
7.4K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
7.4K
01:22Lysosomal Hydrolases
4.7K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
4.7K
01:20Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
226
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
226
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
27
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450...
27
01:27Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
20
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
20